International Journal of Colorectal Disease

, Volume 8, Issue 2, pp 103–105

Lack of prognostic value of immunoreactivity for p62 oncoprotein in colorectal carcinoma

  • K. Matsumoto
  • J. Yamamoto
  • T. Miura
Original Articles
  • 29 Downloads

Abstract

Immunohistochemical staining for c-myc p62 oncoprotein (p62) was performed in 59 colorectal carcinomas using mouse monoclonal antibody against human c-myc protein (MYC1-6E10). The immunoreactivity for p62 was intense in 22 (37.3%), and weak in 37 (62.7%) of the tumors. Advanced disease and nodal metastasis were more frequently seen in tumors showing intense staining but the difference did not reach statistical significance. Sixteeen patients have died of the disease but overall survival rates did not differ between patients with tumours showing intense staining and those with tumors showing weakly staining. In 50 patients undergoing grossly curative resection, local or distant metastasis developed in 15 patients. Immunoreactivity for p62 had no effect on the rate of recurrence or disease free survival rates in these 50 patients undergoing grossly curative resection. The present study revealed that the immunoreactivity for p62 had no prognostic value in colorectal carcinoma.

Résumé

La coloration immuno-histochimique avec la C-MYC p62 oncoprotéine (p62) a été réalisée dans 59 cas de cancer colo-rectal utilisant un anticorps monoclonal de souris contre la protéine humaine C-MYC (MYC1-6E10). L'immunoréactivité pour p62 était intense dans 22 cas (37,3%) et faible chez 37 (62,7%) de ces tumeurs. Une lésion évoluée et des métastases ganglionnaires étaient trouvées plus frequemment dans le groupe des tumeurs montrant une coloration intense mais la différence n'était pas significative. 16 patients sont morts de la maladie, mais les taux de survie totale ne différaient pas entre les patients avec des tumeurs de coloration intense et ceux avec des tumeurs montrant une faible coloration. Chez 50 patients ayant subi une résection grossièrement curative, des métastases locales ou à distance sont survenues chez 15 d'entre eux. L'immunoréactivité pour p62 n'avait pas d'effet sur les taux de récidive ou le pourcentage de survie sans récidive chez ces 50 patients ayant subi une résection grossièrement curative. La présente étude montre que l'immunoréactivité pour p62 n'a pas de valeur pronostique dans le cancer colo-rectal.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Slamon DJ, De Kernion JB, Verma IM, Cline MJ (1984) Expression of cellular oncogenes in human malignancies. Science 224:256–262Google Scholar
  2. 2.
    Alitalio K, Schwab M, Lin CC, Varmus HE, Bishop M (1983) Homogenously staining chromosomal regions contain amplified coplies of abundantly expressed cellular oncogene (c-myc) in malignant endocrine cells from a human colon carcinoma. Proc Natl Acad Sci USA 80:1707–1711Google Scholar
  3. 3.
    Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y (1989) Amplification of c-myc and c-erbB-2 protooncogenes in human solid tumors: Frequency and clinical significance. Int J Cancer 44:802–805Google Scholar
  4. 4.
    Suzuki H, Miura T, Matsumoto K, Ishijima N (1991) Expression of c-myc oncoprotein p62 in normal colon mucosa and colorectal neoplasms: an immuno-histochemical study. Dig Surg 8:19–21Google Scholar
  5. 5.
    Cline MJ, Battifora H, Yokota J (1987) Proto-oncogene abnormalities in human breast cancer; correlation with anatomic features and clinical course of the disease. J Clin Oncol 5:999–1006Google Scholar
  6. 6.
    Locker AP, Dowle CS, Ellis IO, Elston CW, Blamey RW, Sikora K, Evan G, Robins RA (1989) C-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer 60:669–672Google Scholar
  7. 7.
    Ninomiya I, Yonemura Y, Matsumoto H, Sugiyama K, Kamata T, Miwa K, Miyazaki I, Shiku H (1991) Expression of c-myc gene product in gastric carcinoma. Oncology 48:149–153Google Scholar
  8. 8.
    Stewart J, Evan G, Watson J, Sikora K (1986) Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer 53:1–6Google Scholar
  9. 9.
    Finlay GG, Shulz NT, Hill SA, Geiser JR, Ripas JM, Meisler AI (1989) Expression of the myc gene famility in different stages of human colorectal cancer. Oncogene 4:963–971Google Scholar
  10. 10.
    Wynford-Thomas D (1991) Oncogenes and antioncogenes; the molecular basis of tumour behaviour. J Pathol 165:187–201Google Scholar
  11. 11.
    Nagai MA, Habr-Gama A, Oshima CTF, Brentani MM (1992) Association of genetic alterations of c-myc, c-fos, and c-Ha-ras protoocogenes in colorectal tumors. Frequency and clinical significance. Dis Colon Rectum 35:444–451Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • K. Matsumoto
    • 1
  • J. Yamamoto
    • 1
  • T. Miura
    • 1
  1. 1.The Second Department of SurgeryMie University School of MedicineTsu-CityJapan

Personalised recommendations